Pricing Log in Create free account
Friday 6 November 2026 Export STIM’s income statement to Excel — free account

Neuronetics, Inc.

STIM Healthcare Medical Devices

Neuronetics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $149.2 million, up 99.2% from fiscal 2024.

Revenue
+12.5%
EPS
+84.6%
Free cash flow
+237.7%
Total debt
−5.97%

Quarter to September 2026, against a year earlier

2.51 0.08 +3.29%
Market cap
$185.2M
P/E
0.0×
Fwd P/E
−6.5×
Dividend yield
—
F-score
4/9
Altman Z
−3.48
Beneish M
−2.59
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Bought, $m 4.85
Sold, $m 0.28
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — 6 1 2 — 1 1 — 1 —
Sell — — 6 5 — — — — — — — —
Insider Ownership 62.50%

Capital & Financial Ratios $m

Size
Market Cap 185.16
Revenue ttm 159.76
Net income ttm (23.01)
Free cash flow ttm (8.28)
Net debt Q 33.65
Valuation
P/E 0.00
Forward P/E (6.47) (negative: loss-making)
Price / sales 1.18
Forward P/S Powerpack
Price / FCF 0.00
Price / book 8.39 (above 6: high)
Financial health
Current ratio Q 2.01 (at or above 1.5: strong)
Debt / equity Q 2.76 (above 2: weak)
Interest coverage Q 0.25
Growth
Revenue growth Q +12.51% (above 0%: growing)
Operating income growth Q +107.39% (above 0%: growing)
EPS, this year +50.54% (at or above 15%: strong)
EPS, next year A +17.59% (at or above 15%: strong)
Revenue, next year A +8.61%
EPS, past 5 yrs —
EPS, next 5 yrs A +30.48% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 1.5×, against a ten-year median of 1.3×; over the ten years it ranged from 0.1× in 2020 to 7.7× in 2018.
P/S against its own 10 years 38.16%
10-year low 10-year high
P/B against its own 10 years 94.74%
10-year low 10-year high
EV/Sales against its own 10 years 57.38%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 61 20 34 28
Receivables 18 24 17 —
Inventory 8 4 4 5
Other — — — —
94 58 62 54
2023 2024 2025 Q'26
Payables 5 11 11 10
ST’ Debt — — — —
Other — 1 1 0
20 31 31 27

Compound Annual Growth %

10y 5y 3y
Sales — 24.81% 31.76%
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — 0.58% (22.81%)

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate −0.08 Actual −0.02

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q4 FY25 −0.12 −0.10 Beat by 0.02
Q1 FY26 −0.17 −0.16 Beat by 0.01
Q2 FY26 −0.11 −0.05 Beat by 0.06
Q3 FY26 −0.08 −0.02 Beat by 0.06
Q4 FY26 −0.05 — Reports 16 March 2027

EPS $

Mar Jun Sep Dec Year
’26 (0.16) (0.05) (0.02) — —
’25 (0.21) (0.15) (0.13) (0.10) (0.59)
’24 (0.27) (0.33) (0.44) (0.33) (1.37)
’23 (0.38) (0.17) (0.33) (0.19) (1.05)
’22 (0.41) (0.39) (0.28) (0.30) (1.38)
’21 (0.31) (0.29) (0.31) (0.29) (1.22)
’20 (0.68) (0.41) (0.18) (0.19) (1.46)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 34 42 42 — —
’25 32 38 37 42 149
’24 17 16 19 22 75
’23 16 18 18 20 71
’22 14 16 16 18 65
’21 12 14 14 15 55
’20 11 10 12 16 49
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (9) (1) 1 — —
’25 (17) (4) (1) 1 (20)
’24 (12) (5) (5) (9) (31)
’23 (15) (9) (10) 2 (32)
’22 (12) (9) (7) (3) (31)
’21 (9) (6) (9) (5) (28)
’20 (14) (9) (4) (2) (28)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (10) (1) 1 — —
’25 (17) (4) (1) 1 (21)
’24 (12) (6) (6) (9) (32)
’23 (15) (10) (11) 1 (34)
’22 (13) (10) (7) (4) (34)
’21 (10) (6) (9) (5) (30)
’20 (14) (10) (4) (2) (29)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 34 40 53 63 49 55 65 71 75 149 160 +17.8% 162 177 192 +8.7%
Gross margin, % 80.65 76.18 76.42 75.44 76.54 78.93 76.26 72.47 72.32 48.48 50.68 (32.2) pt
EBT (11) (16) (24) (29) (27) (31) (37) (30) (44) (39) (23) +14.9%
EBT margin, % (32.82) (39.72) (45.66) (46.35) (55.75) (56.39) (56.99) (42.31) (58.39) (26.24) (14.40) +6.6 pt
Net income (11) (16) (24) (29) (27) (31) (37) (30) (44) (39) (23) +14.9%
Per share, $
Per share, $ Revenue 234.44 217.38 5.90 3.41 2.61 2.17 2.42 2.49 2.36 2.26 2.07 (40.3%)
Earnings (76.95) (86.34) (2.69) (1.58) (1.46) (1.22) (1.38) (1.05) (1.37) (0.59) (0.33) (41.8%)
Cash flow (58.50) (59.91) (2.30) (1.66) (1.51) (1.10) (1.14) (1.12) (0.98) (0.31) (0.11) (44.2%)
Capex (2.22) (3.19) (0.11) (0.04) (0.04) (0.09) (0.12) (0.08) (0.05) (0.01) 0.00 (44.0%)
Free cash flow (60.72) (63.11) (2.41) (1.70) (1.55) (1.19) (1.26) (1.20) (1.02) (0.32) (0.11) (44.1%)
Book value (32.97) (29.66) 7.94 2.60 1.35 3.34 2.12 1.19 1.00 0.40 0.29 n/m
Shares, m 0 0 9 18 19 25 27 29 32 66 71 +97.2%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
P/S 0.00 0.00 3.28 1.32 4.25 2.05 2.72 1.10 0.68 0.61 1.18 1.6
P/B 0.00 0.00 2.44 1.72 8.21 1.33 3.11 2.31 1.61 3.47 8.39 2.4
EV/Sales 0.00 0.00 1.97 0.59 3.93 0.96 2.17 1.10 1.34 0.91 1.47 1.3
EV/FCF (0.19) (0.19) (4.81) (1.19) (6.65) (1.76) (4.16) (2.28) (3.09) (6.43) (25.55) (3.1)
Cash, $m
Cash, $m Operating cash flow (9) (11) (21) (30) (28) (28) (31) (32) (31) (20) (8) +10.1%
Capex 0 (1) (1) (1) (1) (2) (3) (2) (1) (1) (1) +10.6%
Free cash flow (9) (12) (22) (31) (29) (30) (34) (34) (32) (21) (8) +10.2%
Balance, $m
Balance, $m Working capital 10 25 101 61 51 100 66 74 27 31 27 +13.9%
Net debt 3 0 (74) (45) (16) (60) (36) (1) 35 31 34 +29.4%
Shareholders’ equity (5) (6) 71 48 25 85 57 34 32 26 22 n/m
Returns, %
Returns, % ROA (35.25) (50.39) (30.90) (26.75) (30.70) (28.37) (28.79) (25.95) (34.05) (27.61) (16.64) +7.6 pt
ROIC 0.00 0.00 0.00 (697.81) (141.37) (69.35) (103.82) (58.06) (32.11) (34.06) (16.72) (34.1) pt
ROE 6.08 8.69 39.63 (48.86) (74.86) (56.37) (52.25) (66.17) (132.47) (134.39) (85.85) (140.5) pt
People
People Employees — 167 133 235 126 175 194 203 716 658 — +18.7%
Revenue/emp, $m 0.00 0.24 0.40 0.27 0.39 0.32 0.34 0.35 0.10 0.23 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 4 Nov 2026

Neuronetics, Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
INFU InfuSystems Holdings, Inc. $270.1M 32.0× 33.0× +2.59% (above 0%: growing) +33.33% (above 0%: growing) −66.54% (below 0%: shrinking) 57.98% 11.24% Compare
QSI Quantum-Si Incorporated $256.1M — (loss-making) — (loss-making) −61.59% (below 0%: shrinking) n/m +37.48% (above 0%: growing) 34.91% (11,215.09%) Compare
PROF Profound Medical $251.3M — (loss-making) — (loss-making) +85.86% (above 0%: growing) n/m +47.93% (above 0%: growing) 78.13% (79.56%) Compare
LAB Standard BioTools Inc. $245.7M 1.8× — (loss-making) −0.85% (below 0%: shrinking) n/m +73.32% (above 0%: growing) 55.86% (101.98%) Compare
ELMD Electromed, Inc. $221.8M 19.4× 18.6× +11.64% (above 0%: growing) +57.69% (above 0%: growing) −25.15% (below 0%: shrinking) 78.71% 19.70% Compare
TLSI TriSalus Life Sciences, Inc. $217.4M — (loss-making) — (loss-making) +1.73% (above 0%: growing) n/m −41.29% (below 0%: shrinking) 86.78% (86.03%) Compare
RXST RxSight, Inc. $190.4M — (loss-making) — (loss-making) −18.97% (below 0%: shrinking) n/m +2,591.06% (above 0%: growing) 73.62% (75.32%) Compare
STIM Neuronetics, Inc. $185.2M — (loss-making) — (loss-making) +12.51% (above 0%: growing) n/m +237.71% (above 0%: growing) 52.17% 1.29%
INGN Inogen, Inc $179.7M — (loss-making) — (loss-making) +3.04% (above 0%: growing) n/m −51.15% (below 0%: shrinking) 45.51% (5.36%) Compare
Median of peers $233.8M 19.4× — +2.16% — +6.17% 65.80% (77.44%)

All 149 Medical Devices stocks →

Pay and ownership Proxy statement filed 9 April 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 4.37m 2.20m 20.00
2024 2.43m 1.83m 14.00
2023 2.99m (1.94m) 26.00

Ownership

Directors and executive officers, together 8.40%
Madryn Asset Management, LP and related investment entities 29.80%
Jorey Chernett 14.10%
Parian Ultreia, LP 7.00%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Neuronetics, Inc. (STIM) Latest News

4 Nov

Impact 3 · · GuruFocus.com
Impact 3 · · MarketBeat transcript
Impact 3 · · Moby
Impact 3 · · The Motley Fool transcript
Impact 3 · · InvestorsHub
Impact 3 · · GlobeNewswire

21 Oct

Impact 3 · · GlobeNewswire

8 Sep

Impact 4 ·

18 Aug

Impact 4 · · The Motley Fool transcript

11 Aug

Impact 4 · transcript
Impact 3 · · Moby transcript
Impact 3 · · MarketBeat transcript
Impact 3 · · InvestorsHub
Impact 3 ·

28 Jul

Impact 3 ·

14 May

Impact 4 · · GlobeNewswire

5 May

Impact 4 · · MarketBeat
Impact 4 · · The Motley Fool transcript
Impact 3 · · Moby
Impact 3 · · Zacks
Impact 3 · · GlobeNewswire

2 May

Impact 4 · · Simply Wall St.

18 Apr

Impact 4 · · Simply Wall St.

13 Apr

Impact 4 · · GlobeNewswire

7 Apr

Impact 3 · · GlobeNewswire

6 Apr

Impact 4 · · PR Newswire

3 Apr

Impact 3 · · Simply Wall St.

17 Mar

Impact 4 · · Moby
Impact 4 · · The Motley Fool transcript
Impact 3 · · MarketBeat
stockrow.com/STIM · Data as of Nov 4, 2026 · For information only; not investment advice. · © 2026 stockrow.com